Q3 2016 Earnings Results - November 2016

Third quarter 2016 earnings presentation from a biopharmaceutical company developing prodrug product candidates. The presentation discusses clinical trial plans, regulatory approval strategies including FDA 505(b)(2) pathways and expedited review opportunities, and the company's intellectual property position.